Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Angela C. Tramontano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5718-6297; OpenAlex author ID A5042995297. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper

Papers 9

  1. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  2. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Co-author DOI 10.1097/md.0000000000018082↗
  3. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. Co-author DOI 10.1371/journal.pone.0215409↗
  4. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Co-author DOI 10.1634/theoncologist.2018-0114↗
  5. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. First author DOI 10.1002/cam4.1277↗
  6. Patterns and predictors of end-of-life care in older patients with pancreatic cancer. First author DOI 10.1002/cam4.1861↗
  7. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Co-author DOI 10.1016/j.pan.2018.07.009↗
  8. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. First author DOI 10.1097/mpa.0000000000000587↗
  9. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Co-author DOI 10.1148/radiol.14141282↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chin Hur · 9 shared papers, 2015–2020 · strength 0.77
  2. Chung Yin Kong · 8 shared papers, 2015–2019 · strength 0.66
  3. Pari V. Pandharipande · 6 shared papers, 2015–2019 · strength 0.46
  4. Ryan David Nipp · 3 shared papers, 2018–2019 · strength 0.29
  5. Carlos F. Fernandez-del Castillo · 2 shared papers, 2019–2020 · strength 0.19
  6. Cristina Rosa Ferrone · 2 shared papers, 2019–2020 · strength 0.19
  7. Mary Linton B. Peters · 2 shared papers, 2018–2019 · strength 0.18
  8. Deborah Schrag · 2 shared papers, 2018–2019 · strength 0.17
  9. William Robert Brugge · 2 shared papers, 2015–2016 · strength 0.11
  10. Zhi Ven Fong · 1 shared paper, 2020 · strength 0.11
  11. Andrew Louis Warshaw · 1 shared paper, 2020 · strength 0.11
  12. Naomi M. Sell · 1 shared paper, 2020 · strength 0.11
  13. Motaz Qadan · 1 shared paper, 2020 · strength 0.11
  14. Keith D. Lillemoe · 1 shared paper, 2020 · strength 0.11
  15. Theodore Sunki Hong · 1 shared paper, 2019 · strength 0.08
  16. Jin Choi · 1 shared paper, 2019 · strength 0.08
  17. David P. Ryan · 1 shared paper, 2019 · strength 0.08
  18. Kimiyo N. Yamamoto · 1 shared paper, 2019 · strength 0.08
  19. Akira Nakamura · 1 shared paper, 2019 · strength 0.08
  20. Tetsunosuke Shimizu · 1 shared paper, 2019 · strength 0.08
  21. Kazuhisa Uchiyama · 1 shared paper, 2019 · strength 0.08
  22. Franziska Michor A · 1 shared paper, 2019 · strength 0.08
  23. Hiroshi Haeno · 1 shared paper, 2019 · strength 0.08
  24. Gabriel A. Brooks · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.